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Abstract 
Disorders of the female reproductive system, including those associated with hormone 
regulation, fertility rate and fetal health, are issues of great concern worldwide. More 
recently, melatonin supplementation has been suggested as a therapeutic approach in 
gynecological practice. In both animal models and in women, melatonin supplementation 
suggests a therapeutic and preventative potential, effects attributed mainly to its 
antioxidant properties and action as hormone modulator. The aim of this literature review 
is to further investigate the evidence available on the effects of melatonin 
supplementation in animal and human studies, focusing on its potential application to 
gynecology. Melatonin-containing supplements are easily found in online and high street 
retailers, and despite its supplementation deemed to be relatively safe, no consensus has 
been reached on effective dosage and supplementation period. Short term 
supplementation studies, of up to six months, suggest that a daily posology of 2 to 18 mg 
of melatonin may have the potential to improve fertility rate, oocyte quality, maturation 
and number of embryos. However, the evidence available so far on the effects of 
melatonin supplementation covering gestational age and gestational outcomes is very 
scarce. Clinical trials and longer-term supplementation studies are required to assess any 
clinical outcome associated with melatonin supplementation in the field of gynecology. 
 
Keywords: gynecology; melatonin; reproductive system; antioxidant; fertility. 
1. Introduction  
The mammalian circadian clock covers a wide range of physiological processes and 
plays pivotal role in reproduction [1, 2]. Such physiological processes are coordinated by 
a robust genetic machinery known in lay terms as the "clock genes" [3-6]. Clock genes 
modulate the activity of regulatory nuclei in the hypothalamus-pituitary-gonad axis 
(HPG) and are abundantly expressed in the reproductive tract [3, 4, 7]. It is currently 
accepted that dysregulation of the circadian rhythm caused by night shifts, jet lag and 
sleep deprivation has a detrimental effect on the reproductive system [7-10]. 
A range of blood-borne stimuli and biomolecules contribute to the regulation of the 
circadian system. Melatonin is a hormone and an indolamine synthesized mostly at night, 
as summarized in figure 1. Melatonin is produced not only by the pineal gland, but also 
in glial cells, meningeal cells, and in other peripheral tissues, and its cyclical pattern of 
secretion is responsive to zeitgebers [11].  
 
















Figure 1: Brain circuits involved in melatonin biosynthesis through circadian regulation. 
Adapted from Tan et al. [11]. PIN, pineal gland; PVN, paraventricular nucleus; SCN, 
suprachiasmatic nucleus; SCG, superior cervical ganglion. 
 
 
Melatonin permeability into the central nervous system was described decades ago 
[12] and its efficient transport through the blood-brain-barrier promotes accumulation in 
the brain at levels higher than the ones existing in the blood. Melatonin also possesses 
neuroprotective and antioxidant properties [13-16]. Modulation of redox signaling 
systems influence the reproductive system in both animals and humans [17, 18], and it is 
known that insufficient endogenous production of melatonin has been associated with 
disturbances in the reproductive system due to increased levels of reactive oxygen species 
(ROS), which are harmful to the male and female gametes [19-21]. 
As gametogenesis and gamete viability are negatively associated with increased age, 
successful reproductive strategies are directly related to the life stage of the individual 
[22]. Additionally, unhealthy lifestyles and psychosocial stress are aspects of modern life 
that have a negative impact on gynecological health and reproduction [23-25]. 
Epidemiological studies show that night shifts may negatively influence fetal 
development and may exacerbate gynecological and metabolic disorders, including 
endometriosis, diabetes and obesity [26, 27]. 
Safe and feasible therapeutic strategies are still required to improve gynecological and 
reproductive health. Melatonin-containing supplements are easily found in online and 
high street retailers, with beneficial claims on jet lag [28], as well as occasional sleepiness, 
sleep problems caused by stress, overall mood and overall health.  
Despite melatonin supplementation believed to be relatively safe, there is no 
consensus on any potentially effective dosage, treatment period or whether or not it may 
positively influence gynecological and reproductive health. Melatonin is a key 
neuroendocrine controller in the modulation of the HPG axis, influencing the synthesis 
and secretion of gonadotrophins [29-31]. However, little attention has been paid to its 
potential effects on female health. In this review we aim to address the evidence available 
on pharmacological aspects of melatonin supplementation and further discuss the clinical 
relevance of its supplementation in the field of gynecology and reproduction. 
 
2. Reduction-Oxidation modulation in the ovary 
The antioxidant potential of melatonin has already been investigated, with the 
suggestion that is has protective properties upon several physiological systems [32, 33]. 
Melatonin contributes to the scavenging of free radicals, including hydroxyl cations, at 
the same time stimulating the expression of antioxidant enzymes such as glutathione 
peroxidase, catalase and superoxide dismutase, ultimately modulating the redox balance 
[34, 35]. In the ovary, melatonin shows important actions on mitochondrial protection 
due to enzymatic activation of sirtuin 3 (SIRT3), superoxide dismutase 2 (SOD2) and 
catalase (CAT), also positively modulating the forkhead box O3A (FoxO3a) protein [36]. 
Moreover, melatonin reduces markers of apoptosis (e.g. BAX and caspase 3) and 
increases the expression of the anti-apoptotic B-cell lymphoma-2 (BCL-2) gene [37, 38]. 
Viewed collectively, the linkage of these pathways is shown in figure 2. 
 




Figure 2: Therapeutic potential of melatonin actions in the ovary: Antioxidant, anti-
apoptotic, anti-inflammatory and anti-androgenic regulation. BAX, BCL2 Associated X; 
BCL2, B-cell lymphoma-2; cAMP, Cyclic adenosine monophosphate; FoxO3a, Forkhead 
box O3A; IkBα, Inhibitor of NFkB alpha; IRF3, Interferon regulatory factor 3; NF-kB, 
Nuclear factor kappa B; PKA, Protein kinase A; SIRT3, Sirtuin 3; SOD, Superoxide 
Dysmutase; CAT, Catalase; TRIF, Toll-like receptor-associated activator of interferon. 
 
Given the antioxidant properties of melatonin upon the HPG axis [32, 39, 40], 
melatonin may reduce intra-follicular oxidative damage, also improving progesterone 
production in the luteal phase as well as oocyte maturation [40, 41]. Circulating melatonin 
can be absorbed by the ovary, but the ovarian follicle has the capacity to synthetize and 
secrete its own melatonin, therefore demonstrating an important paracrine role for 
melatonin on the female reproductive system [42, 43]. In addition to its antioxidant 
potential, melatonin has also been employed as a useful clinical tool in ovarian cancer 
due to its anti-proliferative, anti-inflammatory, anti-angiogenic and immunomodulatory 
properties [44]. Melatonin is able to reduce the expression of tumor markers related to 
tumor growth and ovarian metastasis of rats, such as Epidermal growth factor receptors 
2 (Her-2), p38 mitogen-activated protein kinases (p38 MAPK), protein kinase B 
(phospho-AKT) and mammalian target of rapamycin (mTOR) [45]. Melatonin therapy is 
also related to lower expression of other markers, such as ATP synthase subunit β, fatty 
acid-binding protein, and 10-kDa heat shock protein [46]. Similarly, the modulatory 
capacity of melatonin on Toll-like receptors (TLR4-mediated) results in inflammatory 
reduction in the ovary of rats, reducing inflammatory markers such as inhibitor of NFkB 
alpha (IkBα), nuclear factor kappa B (NF-kB), toll-like receptor-associated activator of 
interferon (TRIF) and interferon regulatory factor 3 (IRF3) [47]. 
 
3. The effects of melatonin on reproduction – animal models 
The activity of the reproductive system in mammals is directly linked to food 
availability, environment cues such as temperature and luminosity, and other zeitgebers 
[48]. Retinal receptors transmit environmental cues to the suprachiasmatic nucleus, 
whose activity is inhibited by light and activated by darkness [49, 50]. Consequently, 
changes in the duration of light-dark periods influence sexual activity and reproduction 
[51]. However, such influence appears to be species specific. Longer photoperiods appear 
to show improvement over reproductive parameters in rats [52], whereas shorter 
photoperiods appear to have a detrimental effect [53]. A different response is observed in 
other species; a shorter photoperiod appears to show reproductive advantages in the mare, 
for example [54]. 
Melatonin significantly downregulates gonadotropin-releasing hormone (GnRH) 
mRNA levels in hypothalamic GnRH neurons [55], suggesting a direct effect of 
melatonin over the HPG system. Additionally, an indirect effect also appears to exist; 
melatonin appears to stimulate the gene expression of cyclo-oxygenase 2A (Cox2A), 
influencing the synthesis and secretion of prostaglandins, consequently stimulating 
follicular growth and oocyte maturation [56]. Likewise, melatonin increases the 
expression of kisspeptin proteins, which are important regulatory molecules for the 
secretion of luteinizing hormone [57] and follicle-stimulating hormone [37] [58]. It has 
been shown that the effects of melatonin on improvement of fertility, oocyte development 
and embryo maintenance are attributed to its capacity to reduce oxidative damage in the 
ovarian follicles [59, 60]. At the same time, higher concentrations of melatonin observed 
during pregnancy appear to support fetal maturation and placental homeostasis [59]. 
Pinealectomized rats show impaired ovulation [61, 62]. Upon pinealectomy, the 
decline in serum melatonin is followed by a proliferative response of the endometrium; 
however, melatonin replacement therapy mitigates the morphological dysregulation of its 
epithelium [63]. The presence of melatonin receptors in the endometrium evidences its 
importance in reproduction [64]. Song et al observed that female mice supplemented with 
melatonin added to drinking water for 12 months showed reduced ovary ageing 
parameters, improved quantity and quality of oocytes, and increased litter size [36].  
The effects of melatonin in reproduction and follicular maturation has been 
investigated in non-mammal species, including the zebrafish [56, 65, 66]. Yumnamcha et 
al found that Zebrafish exposed to continuous darkness show higher levels of melatonin 
in the brain and in the ovary than those exposed to continuous light [67]. The authors also 
found that the higher melatonin levels were associated with increased GnRH, decreased 
gonadotropin-inhibiting hormone (GnIH) and improved reproductive rate [67]. 
Furthermore, melatonin appears to play a role in the zebrafish reproductive cycle by 
balancing the synthesis of LH and FSH [56].  
Melatonin is involved in the modulation of Kiss-1 and Kiss-2 gene activities. 
Previously observed in other species, including rat [68] and sheep [69], Kiss-1 and Kiss-
2 enhance reproductive rate and sexual maturation by promoting the secretion of 
gonadotrophins. Clinically, these genes appear to display modulatory roles in the 
reproductive system from puberty to the hormonal cycle phase; mechanistically, Kiss-1 
and Kiss-2 appear to influence the activity of GnRH neurons and mediate metabolic 
factors, such as adipose tissue hormones and energy balance [70]. 
 
 
4. The effects of melatonin on reproduction – human studies 
Metabolic disarrangement, menstrual cycle abnormalities and increased risk of 
miscarriage are manifestations reported in women suffering with polycystic ovary 
syndrome (PCOS)  [71, 72]. In a prospective cohort study including 40 women diagnosed 
with PCOS, melatonin supplementation for six months was effective in restoring their 
menstrual cyclicity and in normalizing androgenic parameters [73]. The antiandrogenic 
potential of melatonin is supported by its capacity to decrease the levels of cyclic AMP 
in granulosa cells (GCs), ultimately reducing the production of androgenic hormones 
[74]. Endometriosis is another condition that results in reproductive dysregulation, and 
can lead to infertility in up to 50% of sufferers [75, 76]. Yang et al observed that 
melatonin supplementation appears to be a feasible adjuvant therapy for endometriosis 
and recurrent spontaneous miscarriage [77], as well as assisting in reduction of pain 
scores and normalization of menstrual disorders such as dysmenorrhea [78]. As melatonin 
crosses the placental barrier, it may have the potential to protect the embryo by reducing 
oxidative damage, possibly hindering the progression of oxidative stress-related fetal 
abnormalities [79]. 
The therapeutic properties of exogenous melatonin may be effective in improving 
fertility rates [80]. As summarized in table 1, melatonin supplementation in disorders of 
the female reproductive system appears to be clinically relevant, improving fertility rate, 
oocyte quality, maturation and number of embryos [15, 81-84]. A randomized double-
blind placebo-controlled study showed that perimenopausal and menopausal women had 
lower salivary melatonin levels, a finding that was positively associated with metabolic 
impairments including lower levels of thyroid hormones [74]. The same study showed 
that after six months of melatonin supplementation, the investigated biomarkers had 
shown signs of improvement, as well as significant improvement in mood and depression 
scores. Another study [85] investigating the effects of melatonin daily supplementation 
for 3 months in postmenopausal women found that the melatonin-receiving group showed 
significant improvement in various climacteric symptoms, including physical, 
psychological and sexual, in comparison to the placebo-receiving group. 
(Insert table 1 here) 









Duration Outcomes References 
Polycystic ovary 
syndrome 
40 23 2mg 6 Months 
Improvement of menstrual irregularities and 
reduction of hyperandrogenism 
[73] 
Endometriosis 40 37 10mg 8 Weeks 
Reduced pain scores and dysmenorrhea 




85 30 3mg Acute Increased mature oocytes and class 1 embryos [83] 
Low fertility rate 18 35 3mg Acute Increased fertility rate [60] 
Low fertility rate 60 30 3mg Acute 
Increased number of mature oocytes and class 1 
embryos 
Increased embryo quality 
[82] 





Increased markers of follicle health and clinical 
pregnancy rates 
[84] 










12 Uninformed 8mg 47 Days 
Reduction of the placental oxidative marker 
malondialdehyde 
[86] 
Pre-eclampsia 68 33 30mg 
Until at 
birth 
Prolonged gestation and reduced the 




240 53 3mg 3 Months Reduced climacteric symptoms [85] 
 Taken together, these findings corroborate the substantial role of melatonin in the 
reproductive axis, whose reduced production upon aging has been associated with the 
onset of menopause [88], thus hindering FSH secretion [57]. 
 
5. 6-sulfatoxymelatonin concentration: a reliable biomarker on gynecology? 
 A surrogate biomarker of melatonin metabolism is 6-sulfatoxymelatonin, a 
melatonin metabolite whose urinary excretion has already been employed in the 
assessment of gynecological disorders [89, 90]. Reduced urinary 6-sulfatoxymelatonin 
levels, associated with higher estradiol and progesterone levels, have been detected in 
women who work rotating night shifts, in comparison to women who work day shifts [91, 
92]. Additionally, decreased circulating levels of 6-sulfatoxymelatonin were reported in 
girls affected by early onset puberty, which evidences the important relationship between 
this biomarker and the female reproductive axis [93]. 
In the opposite direction, Luboshitzky et al detected increased urinary levels of 6-
sulfatoxymelatonin in a cohort of women diagnosed with PCOS, in comparison with non-
PCOS aged-matched women [94], a finding which the authors have associated with the 
androgenic aspects of the syndrome. However, the urinary excretion of 6-
sulfatoxymelatonin does not appear to be a reliable biomarker in patients with 
endometriosis [95, 96]. 
 
 
6. Melatonin in Pregnancy  
A potential application for melatonin supplementation as adjuvant therapy has been 
proposed to aid positive outcomes in pregnancy. Research on melatonin administration 
during the gestational period in animal models appears to suggest a protective mechanism 
upon neurogenesis, placental protection, reduction of oxidative stress, increased 
reproductive rate and improved fetal development [97-99]. The well described crossing 
of melatonin through the placental barrier, and its binding to MT1 and MT2 receptors in 
placental tissue, further evidences its effects upon fetal development; it confirms the role 
of the mother’s own circadian rhythm as the first zeitgeber the fetus is exposed to, which 
in turn modulates fetal neuroendocrine and immune development, and confers antioxidant 
protection [100-105]. 
The antioxidant properties of melatonin upon placental tissue are attributed to its 
capacity to increase the expression of catalase and superoxide dismutase, whilst its 
autocrine and paracrine activities in placental endothelial cells appears to influence the 
development of the fetus’ own circadian system [97-99]. Melatonin receptors expressed 
in the fetal brain are influenced by the mother’s hormone variation, and such role is 
paramount to protect the fetus’ developing brain against oxidative stress and variations in 
oxygen levels [100].  
Potentially beneficial effects of melatonin have been proposed as an appealing 
therapeutic tool in gestational disorders. Fetal growth restriction (FGR) affects 5 to 10% 
of pregnancies, being the second most common cause of perinatal mortality. It is 
associated with fetal hypoxia, nutrient deprivation and imbalanced oxidative stress [106, 
107]. Taking this concern into account, Miller et al. found no safety issues in melatonin 
supplementation for both mother and fetus, and also found reduced levels of 
malondialdehyde, which is a placental oxidative biomarker [86]. 
Pre-eclampsia is another expressive gestational disorder that affects 3 to 10% of 
pregnancies, classically characterized by high blood pressure and proteinuria [108-110]. 
Placental reduction of melatonin receptor (MT1 and MT2) expression, alongside 
inhibition of aralkylamine N-acetyltransferase (AANAT), a key enzyme in melatonin 
synthesis, have been observed in pre-eclampsia [111]. Animal and in vitro studies have 
identified an important protective effect of melatonin administration against gestational 
dysregulations, protecting fetal mitochondria and placental DNA, at the same time 
reducing inflammatory and oxidative biomarkers [87, 112]. In humans, Hobson et al. 
observed that melatonin supplementation prolonged gestation and reduced the dosage of 
antihypertensive drugs [87]; further corroborating the safety of melatonin 
supplementation in pregnancy.  
 
7. Approaches to posology  
The evidence so far available supports the suggestion that melatonin supplementation 
confers positive outcomes in the routine gynecological care, not only improving general 
well-being but also ameliorating reproductive parameters for women of child-bearing age 
who wish to become mothers [101-103]. Further evidence suggests that melatonin confers 
positive outcomes for the musculoskeletal system, improving strength and bone health, 
alongside positive outcomes of psychological nature [104, 113-116]. 
The safety of melatonin supplementation as sleep aid is relatively well documented 
[117]. Its applications in the field of gynecology appear to be not only similarly safe, but 
also promising. Despite the relatively small number of relevant studies available, most of 
them investigating short-term effects, a daily posology ranging from of 2 to 18 mg appears 
to be the most commonly employed, as summarized in Table 1.  
Notwithstanding the apparent safety and allegedly positive health outcomes, robust 
long-term clinical trials that investigate the likelihood and severity of risks associated 
with any melatonin-drug interaction are required before any recommendation can be 
made for expecting mothers. Very long-term studies which investigate the health of 
individuals whose mothers received melatonin supplementation during pregnancy are 
also required to ensure safe recommendations. Directions for future work on melatonin 
supplementation are suggested in Table 2.
(Insert table 2 here) 






Conceptual and Clinical  
 Is chronic melatonin supplementation safe in pregnancy? 
 Is melatonin deficit the culprit for gynecological disorders? Or the other way around? 
 How does the antioxidant effect of melatonin compare with other antioxidant molecules 
for gynecology? 
 What are the effects of melatonin on embryo development? 
 Can melatonin reduce the occurrence of miscarriages? 
 Can melatonin modulate phenotypes related to chromosomal disorders? 
 Can melatonin urinary metabolites be employed as diagnostic tool in clinical practice? 
 Are there adverse effects of melatonin supplementation for the fetus? 
 Is there a safe dose range during pregnancy? 
 
Hormone profile 
 What are the mechanisms involved in the antiandrogenic effect of melatonin? 
 Can melatonin modulate the activity of androgenic receptors? 
 How does melatonin modulate the secretion of estrogen? 
 Can 6-sulfatoxymelatonin metabolite affect the androgenic response? 
 Can 6-sulfatoxymelatonin be an early surrogate biomarker of infertility? 
 Can hormone replacement therapy change plasma levels of melatonin? 
 Can postmenopausal hormone profile affect the melatoninergic response? 
 In what other gynecological disorders can the 6-sulfatoxymelatonin marker be a useful 
clinical tool? 
8. Conclusion 
Melatonin supplementation may offer a therapeutic as well as preventative potential 
in the area of gynecology and obstetrics due to its antioxidant properties and activity as 
hormone modulator. It has been observed in melatonin supplementation studies ranging 
from a few days to up to six months of duration that a daily posology of 2 to 18 mg of 
melatonin appeared to improve fertility rate, oocyte quality, maturation and number of 
embryos. In gestational disorders, daily doses of 8 to 30 mg appeared safe for the mother 
and for the fetus, in addition to an important therapeutic outcome. However, no final 
consensus has yet been reached in respect to effective dose or supplementation period in 
the field of obstetrics and gynecology. Despite melatonin supplementation being 
relatively safe and apparently beneficial, long-term clinical trials are imperative to assess 
further clinical outcomes, with particular attention to the gestational period.  
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Abstract 
Disorders of the female reproductive system, including those associated with hormone 
regulation, fertility rate and fetal health, are issues of great concern worldwide. More 
recently, melatonin supplementation has been suggested as a therapeutic approach in 
gynecological practice. In both animal models and in women, melatonin supplementation 
suggests a therapeutic and preventative potential, effects attributed mainly to its 
antioxidant properties and action as hormone modulator. The aim of this literature review 
is to further investigate the evidence available on the effects of melatonin 
supplementation in animal and human studies, focusing on its potential application to 
gynecology. Melatonin-containing supplements are easily found in online and high street 
retailers, and despite its supplementation deemed to be relatively safe, no consensus has 
been reached on effective dosage and supplementation period. Short term 
supplementation studies, of up to six months, suggest that a daily posology of 2 to 18 mg 
of melatonin may have the potential to improve fertility rate, oocyte quality, maturation 
and number of embryos. However, the evidence available so far on the effects of 
melatonin supplementation covering gestational age and gestational outcomes is very 
scarce. Clinical trials and longer-term supplementation studies are required to assess any 
clinical outcome associated with melatonin supplementation in the field of gynecology. 
 
Keywords: gynecology; melatonin; reproductive system; antioxidant; fertility. 
1. Introduction  
The mammalian circadian clock covers a wide range of physiological processes and 
plays pivotal role in reproduction [1, 2]. Such physiological processes are coordinated by 
a robust genetic machinery known in lay terms as the "clock genes" [3-6]. Clock genes 
modulate the activity of regulatory nuclei in the hypothalamus-pituitary-gonad axis 
(HPG) and are abundantly expressed in the reproductive tract [3, 4, 7]. It is currently 
accepted that dysregulation of the circadian rhythm caused by night shifts, jet lag and 
sleep deprivation has a detrimental effect on the reproductive system [7-10]. 
A range of blood-borne stimuli and biomolecules contribute to the regulation of the 
circadian system. Melatonin is a hormone and an indolamine synthesized mostly at night, 
as summarized in figure 1. Melatonin is produced not only by the pineal gland, but also 
in glial cells, meningeal cells, and in other peripheral tissues, and its cyclical pattern of 
secretion is responsive to zeitgebers [11].  
 
















Figure 1: Brain circuits involved in melatonin biosynthesis through circadian regulation. 
Adapted from Tan et al. [11]. PIN, pineal gland; PVN, paraventricular nucleus; SCN, 
suprachiasmatic nucleus; SCG, superior cervical ganglion. 
 
 
Melatonin permeability into the central nervous system was described decades ago 
[12] and its efficient transport through the blood-brain-barrier promotes accumulation in 
the brain at levels higher than the ones existing in the blood. Melatonin also possesses 
neuroprotective and antioxidant properties [13-16]. Modulation of redox signaling 
systems influence the reproductive system in both animals and humans [17, 18], and it is 
known that insufficient endogenous production of melatonin has been associated with 
disturbances in the reproductive system due to increased levels of reactive oxygen species 
(ROS), which are harmful to the male and female gametes [19-21]. 
As gametogenesis and gamete viability are negatively associated with increased age, 
successful reproductive strategies are directly related to the life stage of the individual 
[22]. Additionally, unhealthy lifestyles and psychosocial stress are aspects of modern life 
that have a negative impact on gynecological health and reproduction [23-25]. 
Epidemiological studies show that night shifts may negatively influence fetal 
development and may exacerbate gynecological and metabolic disorders, including 
endometriosis, diabetes and obesity [26, 27]. 
Safe and feasible therapeutic strategies are still required to improve gynecological and 
reproductive health. Melatonin-containing supplements are easily found in online and 
high street retailers, with beneficial claims on jet lag [28], as well as occasional sleepiness, 
sleep problems caused by stress, overall mood and overall health.  
Despite melatonin supplementation believed to be relatively safe, there is no 
consensus on any potentially effective dosage, treatment period or whether or not it may 
positively influence gynecological and reproductive health. Melatonin is a key 
neuroendocrine controller in the modulation of the HPG axis, influencing the synthesis 
and secretion of gonadotrophins [29-31]. However, little attention has been paid to its 
potential effects on female health. In this review we aim to address the evidence available 
on pharmacological aspects of melatonin supplementation and further discuss the clinical 
relevance of its supplementation in the field of gynecology and reproduction. 
 
2. Reduction-Oxidation modulation in the ovary 
The antioxidant potential of melatonin has already been investigated, with the 
suggestion that is has protective properties upon several physiological systems [32, 33]. 
Melatonin contributes to the scavenging of free radicals, including hydroxyl cations, at 
the same time stimulating the expression of antioxidant enzymes such as glutathione 
peroxidase, catalase and superoxide dismutase, ultimately modulating the redox balance 
[34, 35]. In the ovary, melatonin shows important actions on mitochondrial protection 
due to enzymatic activation of sirtuin 3 (SIRT3), superoxide dismutase 2 (SOD2) and 
catalase (CAT), also positively modulating the forkhead box O3A (FoxO3a) protein [36]. 
Moreover, melatonin reduces markers of apoptosis (e.g. BAX and caspase 3) and 
increases the expression of the anti-apoptotic B-cell lymphoma-2 (BCL-2) gene [37, 38]. 
Viewed collectively, the linkage of these pathways is shown in figure 2. 
 




Figure 2: Therapeutic potential of melatonin actions in the ovary: Antioxidant, anti-
apoptotic, anti-inflammatory and anti-androgenic regulation. BAX, BCL2 Associated X; 
BCL2, B-cell lymphoma-2; cAMP, Cyclic adenosine monophosphate; FoxO3a, Forkhead 
box O3A; IkBα, Inhibitor of NFkB alpha; IRF3, Interferon regulatory factor 3; NF-kB, 
Nuclear factor kappa B; PKA, Protein kinase A; SIRT3, Sirtuin 3; SOD, Superoxide 
Dysmutase; CAT, Catalase; TRIF, Toll-like receptor-associated activator of interferon. 
 
Given the antioxidant properties of melatonin upon the HPG axis [32, 39, 40], 
melatonin may reduce intra-follicular oxidative damage, also improving progesterone 
production in the luteal phase as well as oocyte maturation [40, 41]. Circulating melatonin 
can be absorbed by the ovary, but the ovarian follicle has the capacity to synthetize and 
secrete its own melatonin, therefore demonstrating an important paracrine role for 
melatonin on the female reproductive system [42, 43]. In addition to its antioxidant 
potential, melatonin has also been employed as a useful clinical tool in ovarian cancer 
due to its anti-proliferative, anti-inflammatory, anti-angiogenic and immunomodulatory 
properties [44]. Melatonin is able to reduce the expression of tumor markers related to 
tumor growth and ovarian metastasis of rats, such as Epidermal growth factor receptors 
2 (Her-2), p38 mitogen-activated protein kinases (p38 MAPK), protein kinase B 
(phospho-AKT) and mammalian target of rapamycin (mTOR) [45]. Melatonin therapy is 
also related to lower expression of other markers, such as ATP synthase subunit β, fatty 
acid-binding protein, and 10-kDa heat shock protein [46]. Similarly, the modulatory 
capacity of melatonin on Toll-like receptors (TLR4-mediated) results in inflammatory 
reduction in the ovary of rats, reducing inflammatory markers such as inhibitor of NFkB 
alpha (IkBα), nuclear factor kappa B (NF-kB), toll-like receptor-associated activator of 
interferon (TRIF) and interferon regulatory factor 3 (IRF3) [47]. 
 
3. The effects of melatonin on reproduction – animal models 
The activity of the reproductive system in mammals is directly linked to food 
availability, environment cues such as temperature and luminosity, and other zeitgebers 
[48]. Retinal receptors transmit environmental cues to the suprachiasmatic nucleus, 
whose activity is inhibited by light and activated by darkness [49, 50]. Consequently, 
changes in the duration of light-dark periods influence sexual activity and reproduction 
[51]. However, such influence appears to be species specific. Longer photoperiods appear 
to show improvement over reproductive parameters in rats [52], whereas shorter 
photoperiods appear to have a detrimental effect [53]. A different response is observed in 
other species; a shorter photoperiod appears to show reproductive advantages in the mare, 
for example [54]. 
Melatonin significantly downregulates gonadotropin-releasing hormone (GnRH) 
mRNA levels in hypothalamic GnRH neurons [55], suggesting a direct effect of 
melatonin over the HPG system. Additionally, an indirect effect also appears to exist; 
melatonin appears to stimulate the gene expression of cyclo-oxygenase 2A (Cox2A), 
influencing the synthesis and secretion of prostaglandins, consequently stimulating 
follicular growth and oocyte maturation [56]. Likewise, melatonin increases the 
expression of kisspeptin proteins, which are important regulatory molecules for the 
secretion of luteinizing hormone [57] and follicle-stimulating hormone [37] [58]. It has 
been shown that the effects of melatonin on improvement of fertility, oocyte development 
and embryo maintenance are attributed to its capacity to reduce oxidative damage in the 
ovarian follicles [59, 60]. At the same time, higher concentrations of melatonin observed 
during pregnancy appear to support fetal maturation and placental homeostasis [59]. 
Pinealectomized rats show impaired ovulation [61, 62]. Upon pinealectomy, the 
decline in serum melatonin is followed by a proliferative response of the endometrium; 
however, melatonin replacement therapy mitigates the morphological dysregulation of its 
epithelium [63]. The presence of melatonin receptors in the endometrium evidences its 
importance in reproduction [64]. Song et al observed that female mice supplemented with 
melatonin added to drinking water for 12 months showed reduced ovary ageing 
parameters, improved quantity and quality of oocytes, and increased litter size [36].  
The effects of melatonin in reproduction and follicular maturation has been 
investigated in non-mammal species, including the zebrafish [56, 65, 66]. Yumnamcha et 
al found that Zebrafish exposed to continuous darkness show higher levels of melatonin 
in the brain and in the ovary than those exposed to continuous light [67]. The authors also 
found that the higher melatonin levels were associated with increased GnRH, decreased 
gonadotropin-inhibiting hormone (GnIH) and improved reproductive rate [67]. 
Furthermore, melatonin appears to play a role in the zebrafish reproductive cycle by 
balancing the synthesis of LH and FSH [56].  
Melatonin is involved in the modulation of Kiss-1 and Kiss-2 gene activities. 
Previously observed in other species, including rat [68] and sheep [69], Kiss-1 and Kiss-
2 enhance reproductive rate and sexual maturation by promoting the secretion of 
gonadotrophins. Clinically, these genes appear to display modulatory roles in the 
reproductive system from puberty to the hormonal cycle phase; mechanistically, Kiss-1 
and Kiss-2 appear to influence the activity of GnRH neurons and mediate metabolic 
factors, such as adipose tissue hormones and energy balance [70]. 
 
 
4. The effects of melatonin on reproduction – human studies 
Metabolic disarrangement, menstrual cycle abnormalities and increased risk of 
miscarriage are manifestations reported in women suffering with polycystic ovary 
syndrome (PCOS)  [71, 72]. In a prospective cohort study including 40 women diagnosed 
with PCOS, melatonin supplementation for six months was effective in restoring their 
menstrual cyclicity and in normalizing androgenic parameters [73]. The antiandrogenic 
potential of melatonin is supported by its capacity to decrease the levels of cyclic AMP 
in granulosa cells (GCs), ultimately reducing the production of androgenic hormones 
[74]. Endometriosis is another condition that results in reproductive dysregulation, and 
can lead to infertility in up to 50% of sufferers [75, 76]. Yang et al observed that 
melatonin supplementation appears to be a feasible adjuvant therapy for endometriosis 
and recurrent spontaneous miscarriage [77], as well as assisting in reduction of pain 
scores and normalization of menstrual disorders such as dysmenorrhea [78]. As melatonin 
crosses the placental barrier, it may have the potential to protect the embryo by reducing 
oxidative damage, possibly hindering the progression of oxidative stress-related fetal 
abnormalities [79]. 
The therapeutic properties of exogenous melatonin may be effective in improving 
fertility rates [80]. As summarized in table 1, melatonin supplementation in disorders of 
the female reproductive system appears to be clinically relevant, improving fertility rate, 
oocyte quality, maturation and number of embryos [15, 81-84]. A randomized double-
blind placebo-controlled study showed that perimenopausal and menopausal women had 
lower salivary melatonin levels, a finding that was positively associated with metabolic 
impairments including lower levels of thyroid hormones [74]. The same study showed 
that after six months of melatonin supplementation, the investigated biomarkers had 
shown signs of improvement, as well as significant improvement in mood and depression 
scores. Another study [85] investigating the effects of melatonin daily supplementation 
for 3 months in postmenopausal women found that the melatonin-receiving group showed 
significant improvement in various climacteric symptoms, including physical, 
psychological and sexual, in comparison to the placebo-receiving group. 
(Insert table 1 here) 









Duration Outcomes References 
Polycystic ovary 
syndrome 
40 23 2mg 6 Months 
Improvement of menstrual irregularities and 
reduction of hyperandrogenism 
[73] 
Endometriosis 40 37 10mg 8 Weeks 
Reduced pain scores and dysmenorrhea 




85 30 3mg Acute Increased mature oocytes and class 1 embryos [83] 
Low fertility rate 18 35 3mg Acute Increased fertility rate [60] 
Low fertility rate 60 30 3mg Acute 
Increased number of mature oocytes and class 1 
embryos 
Increased embryo quality 
[82] 





Increased markers of follicle health and clinical 
pregnancy rates 
[84] 










12 Uninformed 8mg 47 Days 
Reduction of the placental oxidative marker 
malondialdehyde 
[86] 
Pre-eclampsia 68 33 30mg 
Until at 
birth 
Prolonged gestation and reduced the 




240 53 3mg 3 Months Reduced climacteric symptoms [85] 
 Taken together, these findings corroborate the substantial role of melatonin in the 
reproductive axis, whose reduced production upon aging has been associated with the 
onset of menopause [88], thus hindering FSH secretion [57]. 
 
5. 6-sulfatoxymelatonin concentration: a reliable biomarker on gynecology? 
 A surrogate biomarker of melatonin metabolism is 6-sulfatoxymelatonin, a 
melatonin metabolite whose urinary excretion has already been employed in the 
assessment of gynecological disorders [89, 90]. Reduced urinary 6-sulfatoxymelatonin 
levels, associated with higher estradiol and progesterone levels, have been detected in 
women who work rotating night shifts, in comparison to women who work day shifts [91, 
92]. Additionally, decreased circulating levels of 6-sulfatoxymelatonin were reported in 
girls affected by early onset puberty, which evidences the important relationship between 
this biomarker and the female reproductive axis [93]. 
In the opposite direction, Luboshitzky et al detected increased urinary levels of 6-
sulfatoxymelatonin in a cohort of women diagnosed with PCOS, in comparison with non-
PCOS aged-matched women [94], a finding which the authors have associated with the 
androgenic aspects of the syndrome. However, the urinary excretion of 6-
sulfatoxymelatonin does not appear to be a reliable biomarker in patients with 
endometriosis [95, 96]. 
 
 
6. Melatonin in Pregnancy  
A potential application for melatonin supplementation as adjuvant therapy has been 
proposed to aid positive outcomes in pregnancy. Research on melatonin administration 
during the gestational period in animal models appears to suggest a protective mechanism 
upon neurogenesis, placental protection, reduction of oxidative stress, increased 
reproductive rate and improved fetal development [97-99]. The well described crossing 
of melatonin through the placental barrier, and its binding to MT1 and MT2 receptors in 
placental tissue, further evidences its effects upon fetal development; it confirms the role 
of the mother’s own circadian rhythm as the first zeitgeber the fetus is exposed to, which 
in turn modulates fetal neuroendocrine and immune development, and confers antioxidant 
protection [100-105]. 
The antioxidant properties of melatonin upon placental tissue are attributed to its 
capacity to increase the expression of catalase and superoxide dismutase, whilst its 
autocrine and paracrine activities in placental endothelial cells appears to influence the 
development of the fetus’ own circadian system [97-99]. Melatonin receptors expressed 
in the fetal brain are influenced by the mother’s hormone variation, and such role is 
paramount to protect the fetus’ developing brain against oxidative stress and variations in 
oxygen levels [100].  
Potentially beneficial effects of melatonin have been proposed as an appealing 
therapeutic tool in gestational disorders. Fetal growth restriction (FGR) affects 5 to 10% 
of pregnancies, being the second most common cause of perinatal mortality. It is 
associated with fetal hypoxia, nutrient deprivation and imbalanced oxidative stress [106, 
107]. Taking this concern into account, Miller et al. found no safety issues in melatonin 
supplementation for both mother and fetus, and also found reduced levels of 
malondialdehyde, which is a placental oxidative biomarker [86]. 
Pre-eclampsia is another expressive gestational disorder that affects 3 to 10% of 
pregnancies, classically characterized by high blood pressure and proteinuria [108-110]. 
Placental reduction of melatonin receptor (MT1 and MT2) expression, alongside 
inhibition of aralkylamine N-acetyltransferase (AANAT), a key enzyme in melatonin 
synthesis, have been observed in pre-eclampsia [111]. Animal and in vitro studies have 
identified an important protective effect of melatonin administration against gestational 
dysregulations, protecting fetal mitochondria and placental DNA, at the same time 
reducing inflammatory and oxidative biomarkers [87, 112]. In humans, Hobson et al. 
observed that melatonin supplementation prolonged gestation and reduced the dosage of 
antihypertensive drugs [87]; further corroborating the safety of melatonin 
supplementation in pregnancy.  
 
7. Approaches to posology  
The evidence so far available supports the suggestion that melatonin supplementation 
confers positive outcomes in the routine gynecological care, not only improving general 
well-being but also ameliorating reproductive parameters for women of child-bearing age 
who wish to become mothers [101-103]. Further evidence suggests that melatonin confers 
positive outcomes for the musculoskeletal system, improving strength and bone health, 
alongside positive outcomes of psychological nature [104, 113-116]. 
The safety of melatonin supplementation as sleep aid is relatively well documented 
[117]. Its applications in the field of gynecology appear to be not only similarly safe, but 
also promising. Despite the relatively small number of relevant studies available, most of 
them investigating short-term effects, a daily posology ranging from of 2 to 18 mg appears 
to be the most commonly employed, as summarized in Table 1.  
Notwithstanding the apparent safety and allegedly positive health outcomes, robust 
long-term clinical trials that investigate the likelihood and severity of risks associated 
with any melatonin-drug interaction are required before any recommendation can be 
made for expecting mothers. Very long-term studies which investigate the health of 
individuals whose mothers received melatonin supplementation during pregnancy are 
also required to ensure safe recommendations. Directions for future work on melatonin 
supplementation are suggested in Table 2.
(Insert table 2 here) 






Conceptual and Clinical  
 Is chronic melatonin supplementation safe in pregnancy? 
 Is melatonin deficit the culprit for gynecological disorders? Or the other way around? 
 How does the antioxidant effect of melatonin compare with other antioxidant molecules 
for gynecology? 
 What are the effects of melatonin on embryo development? 
 Can melatonin reduce the occurrence of miscarriages? 
 Can melatonin modulate phenotypes related to chromosomal disorders? 
 Can melatonin urinary metabolites be employed as diagnostic tool in clinical practice? 
 Are there adverse effects of melatonin supplementation for the fetus? 
 Is there a safe dose range during pregnancy? 
 
Hormone profile 
 What are the mechanisms involved in the antiandrogenic effect of melatonin? 
 Can melatonin modulate the activity of androgenic receptors? 
 How does melatonin modulate the secretion of estrogen? 
 Can 6-sulfatoxymelatonin metabolite affect the androgenic response? 
 Can 6-sulfatoxymelatonin be an early surrogate biomarker of infertility? 
 Can hormone replacement therapy change plasma levels of melatonin? 
 Can postmenopausal hormone profile affect the melatoninergic response? 
 In what other gynecological disorders can the 6-sulfatoxymelatonin marker be a useful 
clinical tool? 
8. Conclusion 
Melatonin supplementation may offer a therapeutic as well as preventative potential 
in the area of gynecology and obstetrics due to its antioxidant properties and activity as 
hormone modulator. It has been observed in melatonin supplementation studies ranging 
from a few days to up to six months of duration that a daily posology of 2 to 18 mg of 
melatonin appeared to improve fertility rate, oocyte quality, maturation and number of 
embryos. In gestational disorders, daily doses of 8 to 30 mg appeared safe for the mother 
and for the fetus, in addition to an important therapeutic outcome. However, no final 
consensus has yet been reached in respect to effective dose or supplementation period in 
the field of obstetrics and gynecology. Despite melatonin supplementation being 
relatively safe and apparently beneficial, long-term clinical trials are imperative to assess 
further clinical outcomes, with particular attention to the gestational period.  
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Abstract 
Disorders of the female reproductive system, including those associated with hormone 
regulation, fertility rate and fetal health, are issues of great concern worldwide. More 
recently, melatonin supplementation has been suggested as a therapeutic approach in 
gynecological practice. In both animal models and in women, melatonin supplementation 
suggests a therapeutic and preventative potential, effects attributed mainly to its 
antioxidant properties and action as hormone modulator. The aim of this literature review 
is to further investigate the evidence available on the effects of melatonin 
supplementation in animal and human studies, focusing on its potential application to 
gynecology. Melatonin-containing supplements are easily found in online and high street 
retailers, and despite its supplementation deemed to be relatively safe, no consensus has 
been reached on effective dosage and supplementation period. Short term 
supplementation studies, of up to six months, suggest that a daily posology of 2 to 18 mg 
of melatonin may have the potential to improve fertility rate, oocyte quality, maturation 
and number of embryos. However, the evidence available so far on the effects of 
melatonin supplementation covering gestational age and gestational outcomes is very 
scarce. Clinical trials and longer-term supplementation studies are required to assess any 
clinical outcome associated with melatonin supplementation in the field of gynecology. 
 
Keywords: gynecology; melatonin; reproductive system; antioxidant; fertility. 
1. Introduction  
The mammalian circadian clock covers a wide range of physiological processes and 
plays pivotal role in reproduction [1, 2]. Such physiological processes are coordinated by 
a robust genetic machinery known in lay terms as the "clock genes" [3-6]. Clock genes 
modulate the activity of regulatory nuclei in the hypothalamus-pituitary-gonad axis 
(HPG) and are abundantly expressed in the reproductive tract [3, 4, 7]. It is currently 
accepted that dysregulation of the circadian rhythm caused by night shifts, jet lag and 
sleep deprivation has a detrimental effect on the reproductive system [7-10]. 
A range of blood-borne stimuli and biomolecules contribute to the regulation of the 
circadian system. Melatonin is a hormone and an indolamine synthesized mostly at night, 
as summarized in figure 1. Melatonin is produced not only by the pineal gland, but also 
in glial cells, meningeal cells, and in other peripheral tissues, and its cyclical pattern of 
secretion is responsive to zeitgebers [11].  
 
















Figure 1: Brain circuits involved in melatonin biosynthesis through circadian regulation. 
Adapted from Tan et al. [11]. PIN, pineal gland; PVN, paraventricular nucleus; SCN, 
suprachiasmatic nucleus; SCG, superior cervical ganglion. 
 
 
Melatonin permeability into the central nervous system was described decades ago 
[12] and its efficient transport through the blood-brain-barrier promotes accumulation in 
the brain at levels higher than the ones existing in the blood. Melatonin also possesses 
neuroprotective and antioxidant properties [13-16]. Modulation of redox signaling 
systems influence the reproductive system in both animals and humans [17, 18], and it is 
known that insufficient endogenous production of melatonin has been associated with 
disturbances in the reproductive system due to increased levels of reactive oxygen species 
(ROS), which are harmful to the male and female gametes [19-21]. 
As gametogenesis and gamete viability are negatively associated with increased age, 
successful reproductive strategies are directly related to the life stage of the individual 
[22]. Additionally, unhealthy lifestyles and psychosocial stress are aspects of modern life 
that have a negative impact on gynecological health and reproduction [23-25]. 
Epidemiological studies show that night shifts may negatively influence fetal 
development and may exacerbate gynecological and metabolic disorders, including 
endometriosis, diabetes and obesity [26, 27]. 
Safe and feasible therapeutic strategies are still required to improve gynecological and 
reproductive health. Melatonin-containing supplements are easily found in online and 
high street retailers, with beneficial claims on jet lag [28], as well as occasional sleepiness, 
sleep problems caused by stress, overall mood and overall health.  
Despite melatonin supplementation believed to be relatively safe, there is no 
consensus on any potentially effective dosage, treatment period or whether or not it may 
positively influence gynecological and reproductive health. Melatonin is a key 
neuroendocrine controller in the modulation of the HPG axis, influencing the synthesis 
and secretion of gonadotrophins [29-31]. However, little attention has been paid to its 
potential effects on female health. In this review we aim to address the evidence available 
on pharmacological aspects of melatonin supplementation and further discuss the clinical 
relevance of its supplementation in the field of gynecology and reproduction. 
 
2. Reduction-Oxidation modulation in the ovary 
The antioxidant potential of melatonin has already been investigated, with the 
suggestion that is has protective properties upon several physiological systems [32, 33]. 
Melatonin contributes to the scavenging of free radicals, including hydroxyl cations, at 
the same time stimulating the expression of antioxidant enzymes such as glutathione 
peroxidase, catalase and superoxide dismutase, ultimately modulating the redox balance 
[34, 35]. In the ovary, melatonin shows important actions on mitochondrial protection 
due to enzymatic activation of sirtuin 3 (SIRT3), superoxide dismutase 2 (SOD2) and 
catalase (CAT), also positively modulating the forkhead box O3A (FoxO3a) protein [36]. 
Moreover, melatonin reduces markers of apoptosis (e.g. BAX and caspase 3) and 
increases the expression of the anti-apoptotic B-cell lymphoma-2 (BCL-2) gene [37, 38]. 
Viewed collectively, the linkage of these pathways is shown in figure 2. 
 




Figure 2: Therapeutic potential of melatonin actions in the ovary: Antioxidant, anti-
apoptotic, anti-inflammatory and anti-androgenic regulation. BAX, BCL2 Associated X; 
BCL2, B-cell lymphoma-2; cAMP, Cyclic adenosine monophosphate; FoxO3a, Forkhead 
box O3A; IkBα, Inhibitor of NFkB alpha; IRF3, Interferon regulatory factor 3; NF-kB, 
Nuclear factor kappa B; PKA, Protein kinase A; SIRT3, Sirtuin 3; SOD, Superoxide 
Dysmutase; CAT, Catalase; TRIF, Toll-like receptor-associated activator of interferon. 
 
Given the antioxidant properties of melatonin upon the HPG axis [32, 39, 40], 
melatonin may reduce intra-follicular oxidative damage, also improving progesterone 
production in the luteal phase as well as oocyte maturation [40, 41]. Circulating melatonin 
can be absorbed by the ovary, but the ovarian follicle has the capacity to synthetize and 
secrete its own melatonin, therefore demonstrating an important paracrine role for 
melatonin on the female reproductive system [42, 43]. In addition to its antioxidant 
potential, melatonin has also been employed as a useful clinical tool in ovarian cancer 
due to its anti-proliferative, anti-inflammatory, anti-angiogenic and immunomodulatory 
properties [44]. Melatonin is able to reduce the expression of tumor markers related to 
tumor growth and ovarian metastasis of rats, such as Epidermal growth factor receptors 
2 (Her-2), p38 mitogen-activated protein kinases (p38 MAPK), protein kinase B 
(phospho-AKT) and mammalian target of rapamycin (mTOR) [45]. Melatonin therapy is 
also related to lower expression of other markers, such as ATP synthase subunit β, fatty 
acid-binding protein, and 10-kDa heat shock protein [46]. Similarly, the modulatory 
capacity of melatonin on Toll-like receptors (TLR4-mediated) results in inflammatory 
reduction in the ovary of rats, reducing inflammatory markers such as inhibitor of NFkB 
alpha (IkBα), nuclear factor kappa B (NF-kB), toll-like receptor-associated activator of 
interferon (TRIF) and interferon regulatory factor 3 (IRF3) [47]. 
 
3. The effects of melatonin on reproduction – animal models 
The activity of the reproductive system in mammals is directly linked to food 
availability, environment cues such as temperature and luminosity, and other zeitgebers 
[48]. Retinal receptors transmit environmental cues to the suprachiasmatic nucleus, 
whose activity is inhibited by light and activated by darkness [49, 50]. Consequently, 
changes in the duration of light-dark periods influence sexual activity and reproduction 
[51]. However, such influence appears to be species specific. Longer photoperiods appear 
to show improvement over reproductive parameters in rats [52], whereas shorter 
photoperiods appear to have a detrimental effect [53]. A different response is observed in 
other species; a shorter photoperiod appears to show reproductive advantages in the mare, 
for example [54]. 
Melatonin significantly downregulates gonadotropin-releasing hormone (GnRH) 
mRNA levels in hypothalamic GnRH neurons [55], suggesting a direct effect of 
melatonin over the HPG system. Additionally, an indirect effect also appears to exist; 
melatonin appears to stimulate the gene expression of cyclo-oxygenase 2A (Cox2A), 
influencing the synthesis and secretion of prostaglandins, consequently stimulating 
follicular growth and oocyte maturation [56]. Likewise, melatonin increases the 
expression of kisspeptin proteins, which are important regulatory molecules for the 
secretion of luteinizing hormone [57] and follicle-stimulating hormone [37] [58]. It has 
been shown that the effects of melatonin on improvement of fertility, oocyte development 
and embryo maintenance are attributed to its capacity to reduce oxidative damage in the 
ovarian follicles [59, 60]. At the same time, higher concentrations of melatonin observed 
during pregnancy appear to support fetal maturation and placental homeostasis [59]. 
Pinealectomized rats show impaired ovulation [61, 62]. Upon pinealectomy, the 
decline in serum melatonin is followed by a proliferative response of the endometrium; 
however, melatonin replacement therapy mitigates the morphological dysregulation of its 
epithelium [63]. The presence of melatonin receptors in the endometrium evidences its 
importance in reproduction [64]. Song et al observed that female mice supplemented with 
melatonin added to drinking water for 12 months showed reduced ovary ageing 
parameters, improved quantity and quality of oocytes, and increased litter size [36].  
The effects of melatonin in reproduction and follicular maturation has been 
investigated in non-mammal species, including the zebrafish [56, 65, 66]. Yumnamcha et 
al found that Zebrafish exposed to continuous darkness show higher levels of melatonin 
in the brain and in the ovary than those exposed to continuous light [67]. The authors also 
found that the higher melatonin levels were associated with increased GnRH, decreased 
gonadotropin-inhibiting hormone (GnIH) and improved reproductive rate [67]. 
Furthermore, melatonin appears to play a role in the zebrafish reproductive cycle by 
balancing the synthesis of LH and FSH [56].  
Melatonin is involved in the modulation of Kiss-1 and Kiss-2 gene activities. 
Previously observed in other species, including rat [68] and sheep [69], Kiss-1 and Kiss-
2 enhance reproductive rate and sexual maturation by promoting the secretion of 
gonadotrophins. Clinically, these genes appear to display modulatory roles in the 
reproductive system from puberty to the hormonal cycle phase; mechanistically, Kiss-1 
and Kiss-2 appear to influence the activity of GnRH neurons and mediate metabolic 
factors, such as adipose tissue hormones and energy balance [70]. 
 
 
4. The effects of melatonin on reproduction – human studies 
Metabolic disarrangement, menstrual cycle abnormalities and increased risk of 
miscarriage are manifestations reported in women suffering with polycystic ovary 
syndrome (PCOS)  [71, 72]. In a prospective cohort study including 40 women diagnosed 
with PCOS, melatonin supplementation for six months was effective in restoring their 
menstrual cyclicity and in normalizing androgenic parameters [73]. The antiandrogenic 
potential of melatonin is supported by its capacity to decrease the levels of cyclic AMP 
in granulosa cells (GCs), ultimately reducing the production of androgenic hormones 
[74]. Endometriosis is another condition that results in reproductive dysregulation, and 
can lead to infertility in up to 50% of sufferers [75, 76]. Yang et al observed that 
melatonin supplementation appears to be a feasible adjuvant therapy for endometriosis 
and recurrent spontaneous miscarriage [77], as well as assisting in reduction of pain 
scores and normalization of menstrual disorders such as dysmenorrhea [78]. As melatonin 
crosses the placental barrier, it may have the potential to protect the embryo by reducing 
oxidative damage, possibly hindering the progression of oxidative stress-related fetal 
abnormalities [79]. 
The therapeutic properties of exogenous melatonin may be effective in improving 
fertility rates [80]. As summarized in table 1, melatonin supplementation in disorders of 
the female reproductive system appears to be clinically relevant, improving fertility rate, 
oocyte quality, maturation and number of embryos [15, 81-84]. A randomized double-
blind placebo-controlled study showed that perimenopausal and menopausal women had 
lower salivary melatonin levels, a finding that was positively associated with metabolic 
impairments including lower levels of thyroid hormones [74]. The same study showed 
that after six months of melatonin supplementation, the investigated biomarkers had 
shown signs of improvement, as well as significant improvement in mood and depression 
scores. Another study [85] investigating the effects of melatonin daily supplementation 
for 3 months in postmenopausal women found that the melatonin-receiving group showed 
significant improvement in various climacteric symptoms, including physical, 
psychological and sexual, in comparison to the placebo-receiving group. 
(Insert table 1 here) 









Duration Outcomes References 
Polycystic ovary 
syndrome 
40 23 2mg 6 Months 
Improvement of menstrual irregularities and 
reduction of hyperandrogenism 
[73] 
Endometriosis 40 37 10mg 8 Weeks 
Reduced pain scores and dysmenorrhea 




85 30 3mg Acute Increased mature oocytes and class 1 embryos [83] 
Low fertility rate 18 35 3mg Acute Increased fertility rate [60] 
Low fertility rate 60 30 3mg Acute 
Increased number of mature oocytes and class 1 
embryos 
Increased embryo quality 
[82] 





Increased markers of follicle health and clinical 
pregnancy rates 
[84] 










12 Uninformed 8mg 47 Days 
Reduction of the placental oxidative marker 
malondialdehyde 
[86] 
Pre-eclampsia 68 33 30mg 
Until at 
birth 
Prolonged gestation and reduced the 




240 53 3mg 3 Months Reduced climacteric symptoms [85] 
 Taken together, these findings corroborate the substantial role of melatonin in the 
reproductive axis, whose reduced production upon aging has been associated with the 
onset of menopause [88], thus hindering FSH secretion [57]. 
 
5. 6-sulfatoxymelatonin concentration: a reliable biomarker on gynecology? 
 A surrogate biomarker of melatonin metabolism is 6-sulfatoxymelatonin, a 
melatonin metabolite whose urinary excretion has already been employed in the 
assessment of gynecological disorders [89, 90]. Reduced urinary 6-sulfatoxymelatonin 
levels, associated with higher estradiol and progesterone levels, have been detected in 
women who work rotating night shifts, in comparison to women who work day shifts [91, 
92]. Additionally, decreased circulating levels of 6-sulfatoxymelatonin were reported in 
girls affected by early onset puberty, which evidences the important relationship between 
this biomarker and the female reproductive axis [93]. 
In the opposite direction, Luboshitzky et al detected increased urinary levels of 6-
sulfatoxymelatonin in a cohort of women diagnosed with PCOS, in comparison with non-
PCOS aged-matched women [94], a finding which the authors have associated with the 
androgenic aspects of the syndrome. However, the urinary excretion of 6-
sulfatoxymelatonin does not appear to be a reliable biomarker in patients with 
endometriosis [95, 96]. 
 
 
6. Melatonin in Pregnancy  
A potential application for melatonin supplementation as adjuvant therapy has been 
proposed to aid positive outcomes in pregnancy. Research on melatonin administration 
during the gestational period in animal models appears to suggest a protective mechanism 
upon neurogenesis, placental protection, reduction of oxidative stress, increased 
reproductive rate and improved fetal development [97-99]. The well described crossing 
of melatonin through the placental barrier, and its binding to MT1 and MT2 receptors in 
placental tissue, further evidences its effects upon fetal development; it confirms the role 
of the mother’s own circadian rhythm as the first zeitgeber the fetus is exposed to, which 
in turn modulates fetal neuroendocrine and immune development, and confers antioxidant 
protection [100-105]. 
The antioxidant properties of melatonin upon placental tissue are attributed to its 
capacity to increase the expression of catalase and superoxide dismutase, whilst its 
autocrine and paracrine activities in placental endothelial cells appears to influence the 
development of the fetus’ own circadian system [97-99]. Melatonin receptors expressed 
in the fetal brain are influenced by the mother’s hormone variation, and such role is 
paramount to protect the fetus’ developing brain against oxidative stress and variations in 
oxygen levels [100].  
Potentially beneficial effects of melatonin have been proposed as an appealing 
therapeutic tool in gestational disorders. Fetal growth restriction (FGR) affects 5 to 10% 
of pregnancies, being the second most common cause of perinatal mortality. It is 
associated with fetal hypoxia, nutrient deprivation and imbalanced oxidative stress [106, 
107]. Taking this concern into account, Miller et al. found no safety issues in melatonin 
supplementation for both mother and fetus, and also found reduced levels of 
malondialdehyde, which is a placental oxidative biomarker [86]. 
Pre-eclampsia is another expressive gestational disorder that affects 3 to 10% of 
pregnancies, classically characterized by high blood pressure and proteinuria [108-110]. 
Placental reduction of melatonin receptor (MT1 and MT2) expression, alongside 
inhibition of aralkylamine N-acetyltransferase (AANAT), a key enzyme in melatonin 
synthesis, have been observed in pre-eclampsia [111]. Animal and in vitro studies have 
identified an important protective effect of melatonin administration against gestational 
dysregulations, protecting fetal mitochondria and placental DNA, at the same time 
reducing inflammatory and oxidative biomarkers [87, 112]. In humans, Hobson et al. 
observed that melatonin supplementation prolonged gestation and reduced the dosage of 
antihypertensive drugs [87]; further corroborating the safety of melatonin 
supplementation in pregnancy.  
 
7. Approaches to posology  
The evidence so far available supports the suggestion that melatonin supplementation 
confers positive outcomes in the routine gynecological care, not only improving general 
well-being but also ameliorating reproductive parameters for women of child-bearing age 
who wish to become mothers [101-103]. Further evidence suggests that melatonin confers 
positive outcomes for the musculoskeletal system, improving strength and bone health, 
alongside positive outcomes of psychological nature [104, 113-116]. 
The safety of melatonin supplementation as sleep aid is relatively well documented 
[117]. Its applications in the field of gynecology appear to be not only similarly safe, but 
also promising. Despite the relatively small number of relevant studies available, most of 
them investigating short-term effects, a daily posology ranging from of 2 to 18 mg appears 
to be the most commonly employed, as summarized in Table 1.  
Notwithstanding the apparent safety and allegedly positive health outcomes, robust 
long-term clinical trials that investigate the likelihood and severity of risks associated 
with any melatonin-drug interaction are required before any recommendation can be 
made for expecting mothers. Very long-term studies which investigate the health of 
individuals whose mothers received melatonin supplementation during pregnancy are 
also required to ensure safe recommendations. Directions for future work on melatonin 
supplementation are suggested in Table 2.
(Insert table 2 here) 






Conceptual and Clinical  
 Is chronic melatonin supplementation safe in pregnancy? 
 Is melatonin deficit the culprit for gynecological disorders? Or the other way around? 
 How does the antioxidant effect of melatonin compare with other antioxidant molecules 
for gynecology? 
 What are the effects of melatonin on embryo development? 
 Can melatonin reduce the occurrence of miscarriages? 
 Can melatonin modulate phenotypes related to chromosomal disorders? 
 Can melatonin urinary metabolites be employed as diagnostic tool in clinical practice? 
 Are there adverse effects of melatonin supplementation for the fetus? 
 Is there a safe dose range during pregnancy? 
 
Hormone profile 
 What are the mechanisms involved in the antiandrogenic effect of melatonin? 
 Can melatonin modulate the activity of androgenic receptors? 
 How does melatonin modulate the secretion of estrogen? 
 Can 6-sulfatoxymelatonin metabolite affect the androgenic response? 
 Can 6-sulfatoxymelatonin be an early surrogate biomarker of infertility? 
 Can hormone replacement therapy change plasma levels of melatonin? 
 Can postmenopausal hormone profile affect the melatoninergic response? 
 In what other gynecological disorders can the 6-sulfatoxymelatonin marker be a useful 
clinical tool? 
8. Conclusion 
Melatonin supplementation may offer a therapeutic as well as preventative potential 
in the area of gynecology and obstetrics due to its antioxidant properties and activity as 
hormone modulator. It has been observed in melatonin supplementation studies ranging 
from a few days to up to six months of duration that a daily posology of 2 to 18 mg of 
melatonin appeared to improve fertility rate, oocyte quality, maturation and number of 
embryos. In gestational disorders, daily doses of 8 to 30 mg appeared safe for the mother 
and for the fetus, in addition to an important therapeutic outcome. However, no final 
consensus has yet been reached in respect to effective dose or supplementation period in 
the field of obstetrics and gynecology. Despite melatonin supplementation being 
relatively safe and apparently beneficial, long-term clinical trials are imperative to assess 
further clinical outcomes, with particular attention to the gestational period.  
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